Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
829,922

-0.02 (-0.53%)

Updated Nov 11, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

by Zacks Equity Research

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss

by Zacks Equity Research

Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.

Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

by Zacks Equity Research

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0.00% and 41.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?